Eisai mulls NICE appeal after another no for Halaven
This article was originally published in Scrip
Eisai is taking legal advice on whether it will appeal against negative final draft guidance from NICE, the health technology assessor for England and Wales, which rejects Halaven (eribulin), an end of life breast cancer drug. New economic modelling and an additional subgroup analysis failed to reassure NICE about its doubts over the drug's side effects and cost-effectiveness.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.